252 related articles for article (PubMed ID: 25716744)
1. Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status.
Bourdillon P; Hlaihel C; Guyotat J; Guillotton L; Honnorat J; Ducray F; Cotton F
J Neurooncol; 2015 May; 122(3):529-37. PubMed ID: 25716744
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms.
Singh VY; Chacko G; Chacko AG; Rajshekhar V
Neurol India; 2014; 62(1):32-6. PubMed ID: 24608451
[TBL] [Abstract][Full Text] [Related]
3. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
Reyes-Botero G; Dehais C; Idbaih A; Martin-Duverneuil N; Lahutte M; Carpentier C; Letouzé E; Chinot O; Loiseau H; Honnorat J; Ramirez C; Moyal E; Figarella-Branger D; Ducray F;
Neuro Oncol; 2014 May; 16(5):662-70. PubMed ID: 24353325
[TBL] [Abstract][Full Text] [Related]
4. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
5. Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?
Fellah S; Caudal D; De Paula AM; Dory-Lautrec P; Figarella-Branger D; Chinot O; Metellus P; Cozzone PJ; Confort-Gouny S; Ghattas B; Callot V; Girard N
AJNR Am J Neuroradiol; 2013 Jul; 34(7):1326-33. PubMed ID: 23221948
[TBL] [Abstract][Full Text] [Related]
6. Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.
Iwadate Y; Matsutani T; Hasegawa Y; Shinozaki N; Higuchi Y; Saeki N
J Neurooncol; 2011 May; 102(3):443-9. PubMed ID: 20721680
[TBL] [Abstract][Full Text] [Related]
7. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
[TBL] [Abstract][Full Text] [Related]
8. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status.
Katsetos CD; Del Valle L; Geddes JF; Aldape K; Boyd JC; Legido A; Khalili K; Perentes E; Mörk SJ
J Neuropathol Exp Neurol; 2002 Apr; 61(4):307-20. PubMed ID: 11939586
[TBL] [Abstract][Full Text] [Related]
9. Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion.
Pai T; Epari S; Desai S; Wadile A; Gupta T; Goda JS; Moiyadi A; Shetty P; Kane S; Jalali R
Neurol India; 2017; 65(1):113-120. PubMed ID: 28084254
[TBL] [Abstract][Full Text] [Related]
10. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
Snuderl M; Eichler AF; Ligon KL; Vu QU; Silver M; Betensky RA; Ligon AH; Wen PY; Louis DN; Iafrate AJ
Clin Cancer Res; 2009 Oct; 15(20):6430-7. PubMed ID: 19808867
[TBL] [Abstract][Full Text] [Related]
11. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
[TBL] [Abstract][Full Text] [Related]
12. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.
Figarella-Branger D; Mokhtari K; Dehais C; Jouvet A; Uro-Coste E; Colin C; Carpentier C; Forest F; Maurage CA; Vignaud JM; Polivka M; Lechapt-Zalcman E; Eimer S; Viennet G; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Loussouarn D; Lacroix C; Rigau V; Laquerrière A; Vandenbos F; Michalak S; Sevestre H; Peoch M; Labrousse F; Christov C; Kemeny JL; Chenard MP; Chiforeanu D; Ducray F; Idbaih A;
Neuro Oncol; 2014 Sep; 16(9):1244-54. PubMed ID: 24723566
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas.
Hlaihel C; Guilloton L; Guyotat J; Streichenberger N; Honnorat J; Cotton F
J Neurooncol; 2010 Mar; 97(1):73-80. PubMed ID: 19727562
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.
Li J; Miao N; Liu M; Cui W; Liu X; Li X; Shi X; Qing S; Ma Y; Zhang W; Biekemituofu H
Int J Clin Exp Pathol; 2014; 7(12):8609-15. PubMed ID: 25674225
[TBL] [Abstract][Full Text] [Related]
15. MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status.
Sherman JH; Prevedello DM; Shah L; Raghavan P; Pouratian N; Starke RM; Lopes MB; Shaffrey ME; Schiff D
Acta Neurochir (Wien); 2010 Nov; 152(11):1827-34. PubMed ID: 20711790
[TBL] [Abstract][Full Text] [Related]
16. Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
Branzoli F; Pontoizeau C; Tchara L; Di Stefano AL; Kamoun A; Deelchand DK; Valabrègue R; Lehéricy S; Sanson M; Ottolenghi C; Marjańska M
Neuro Oncol; 2019 Jun; 21(6):765-774. PubMed ID: 30726924
[TBL] [Abstract][Full Text] [Related]
17. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
[TBL] [Abstract][Full Text] [Related]
18. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
[TBL] [Abstract][Full Text] [Related]
19. Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion.
Marucci G; Di Oto E; Farnedi A; Panzacchi R; Ligorio C; Foschini MP
Hum Pathol; 2012 Mar; 43(3):374-80. PubMed ID: 21835431
[TBL] [Abstract][Full Text] [Related]
20. Association of 1p/19q Codeletion and Radiation Necrosis in Adult Cranial Gliomas After Proton or Photon Therapy.
Acharya S; Robinson CG; Michalski JM; Mullen D; DeWees TA; Campian JL; Chundury A; Bottani B; Hallahan DE; Bradley JD; Huang J
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):334-343. PubMed ID: 29534896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]